AP NEWS

The Center for Biosimilars® to Launch Biosimilars Stakeholders Summit

November 12, 2018

CRANBURY, N.J.--(BUSINESS WIRE)--Nov 12, 2018--The Center for Biosimilars®, an online resource for emerging therapies that focuses on improving patient outcomes, will present its latest Peer Exchange titled, “Biosimilars Stakeholders Summit: Best Practices for Biosimilars Education and Promotion” on Thursday, Dec. 13, at 12 p.m., 3 p.m., and 6 p.m. EST.

“This exchange is designed to bring together expertise from both producers and prescribers of biosimilar products to explore the educational needs of the market and how to address them,” said Jeff Prescott, PharmD, senior vice president with The Center for Biosimilars®. “Our expert panelists will cover relevant topics, from the current understanding of biosimilars to identifying challenges in differentiating biosimilar products.”

This summit will feature Gillian Woollett, MA, senior vice president, Avalere Health, as the moderator; and Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP, clinical coordinator, hematology-oncology, University of Arizona Cancer Center, president-elect, Association of Community Cancer Centers; Juliana Reed, vice president, corporate affairs lead—PEH Global Biosimilars at Pfizer, president, The Biosimilars Forum; Carlos Sattler, M.D., vice president and head, clinical development and medical affairs, Sandoz; and Kashyap Patel, M.D, chief executive officer, Carolina Blood and Cancer Care, as the four panelists who will provide an overview of the current understanding of biosimilar products in the marketplace, identify unmet needs and challenges in differentiating biosimilar products from originators, and evaluate appropriate and responsible messaging for positioning biosimilar products in the marketplace.

The Biosimilars Stakeholder Summit, which is a lively peer-to-peer discussion, brings together authoritative industry leaders to discuss appropriate educational and awareness messages and tactics that will inform practitioners, payers, and patients about the role and position of biosimilar products in patient care.

For registration and more information, please visit, https://www.centerforbiosimilars.com/webinars/stakeholders-summit

About The Center for Biosimilars®

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Biosimilars®, which was cited in a United States Senate testimony on drug prices and out-of-pocket costs for rheumatoid arthritis drugs, discusses the current landscape for advanced health care management.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181112005606/en/

CONTACT: The Center for Biosimilars Media:

Alexandra Ventura, 609-716-7777, ext. 121

aventura@mjhassoc.com

or

John Patricolo, 609-325-4630, ext. 133

jpatricolo@mjhassoc.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE

SOURCE: The Center for Biosimilars

Copyright Business Wire 2018.

PUB: 11/12/2018 11:46 AM/DISC: 11/12/2018 11:46 AM

http://www.businesswire.com/news/home/20181112005606/en

AP RADIO
Update hourly